Platelets and thrombolytic therapy

New England Journal of Medicine

Volumn 322, Issue 1, 1990, Pages 33-42

  Flier, Jeffrey S ^a   Underhill, Lisa H ^a   Coller, Barry S ^b  

^a State University of New York at Stony Brook ^*

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXYDIBENZO[B,F]THIEPIN 5,5 DIOXIDE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; FIBRINOLYTIC AGENT; PIRMAGREL; RIDOGREL; STREPTOKINASE; SULOTROBAN; TISSUE PLASMINOGEN ACTIVATOR; VAPIPROST;

BLEEDING; FIBRINOLYSIS; HUMAN; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

BLOOD PLATELETS; HUMAN; PLATELET AGGREGATION INHIBITORS; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOLYTIC THERAPY; VASCULAR DISEASES;

EID: 0025097994     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199001043220107     Document Type: Review

References (147)

1. Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med 1988; 318: 1512–20, 1585–95.
2. Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med 1988; 319: 925–31.
3. Runge MS, Quertermous T, Haber E. Plasminogen activators: the old and the new. Circulation 1989; 79: 217–24.
4. Leonard EF, Turitto VT, Vroman L, eds. Blood in contact with natural and artificial surfaces. Ann N Y Acad Sci 1987; 516: 1–688.
5. Walsh PN. Platelet-mediated coagulant protein interactions in hemostasis. Semin Hematol 1985; 22: 178–86.
6. Haerem JW. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly from coronary artery disease. Atherosclerosis 1972; 15: 199–213.
7. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699–708.
8. Davies MJ, Thomas achéal, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73: 418–27.
9. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985; 5: Suppl: 175B–184B.
10. Maseri A, Chierchia S, Davies G. Pathophysiology of coronary occlusion in acute infarction. Circulation 1986; 73: 233–9.
11. Harker LA. Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation 1986; 73: 206–23.
12. George JN, Nurden AT, Phillips DR, eds. Platelet membrane glycoproteins. New York: Plenum, 1985.
13. Kunicki TJ, Nugent DJ, Staats SJ, Orchekowski RP, Wayner EA, Carter WG. The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex. J Biol Chem 1988; 263: 4516–9.
14. Santoro SA, Rajpara SM, Staatz WD, Woods VL Jr. Isolation and characterization of a platelet surface collagen binding complex related to VLA-2. Biochem Biophys Res Commun 1988; 153: 217–23.
15. Piotrowicz RS, Orchekowski RP, Nugent DJ, Yamada KY, Kunicki TJ. Glycoprotein Ic-IIa functions as an activation-independent fibronectin receptor on human platelets. J Cell Biol 1988; 106: 1359–64.
16. Lam SC, Plow EF, D'Souza SE, Cheresh DA, Frelinger AL III, Ginsberg MH. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem 1989; 264: 3742–9.
17. Hemler ME, Crouse C, Takada Y, Sonnenberg A. Multiple very late antigen (VLA) heterodimers on platelets: evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures. J Biol Chem 1988; 263: 7660–5.
18. Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. Nature 1988; 336: 487–9.
19. Plow EF, Ginsberg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1989; 9: 117–56.
20. Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood 1989; 74: 182–92.
21. Asch AS, Barnwell J, Silverstein RL, Nachman RL. Isolation of the thrombospondin membrane receptor. J Clin Invest 1987, 79: 1054–61.
22. Tandon NN, Kralisz U, Jamieson GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 1989; 264: 7576–83.
23. Lawler J, Hynes RO. An integrin on normal and thrombasthenic platelets which binds thrombospondin. Blood 1989; 74: 2022–7.
24. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549–54.
25. Peerschke EI. The platelet fibrinogen receptor. Semin Hematol 1985; 22: 241–59.
26. Plow EF, McEver RP, Coller BS, Woods VL Jr, Marguerie GA, Ginsberg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724–7.
27. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb/IIIa complex at high shear rate. J Clin Invest 1989; 83: 288–97.
28. Schullek J, Jordan J, Montgomery RR. Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest 1984; 73: 421–8.
29. Gralnick HR, Williams SB, Coller BS. Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin. Blood 1984; 64: 797–800.
30. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A 1985; 82: 8057–61.
31. Haverstick DM, Cowan JF, Yamada KM, Santoro SA. Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin. Blood 1985; 66: 946–52.
32. Gartner TK, Bennett JS. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J Biol Chem 1985; 260: 11891–4.
33. Coller BS. Activation-specific platelet antigens. In: Kunicki TJ, ed. Platelet immunobiology: molecular and clinical aspects. Philadelphia: J.B. Lippincott, 1989:166–89.
34. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325–38.
35. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ II. Clinical implications of prostaglandin and thromboxane A2 formation. N Engl J Med 1988; 319: 689–98, 761–7.
36. Marcus AJ. Transcellular metabolism of eicosanoids. Prog Hemost Thromb 1986; 8: 127–42.
37. Nowak J, FitzGerald GA. Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 1989; 83: 380–5.
38. Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis: studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987; 80: 1435–45.
39. Kinlough-Rathbone RL, Packham MA, Mustard JF. The effect of prostaglandin E1 on platelet function in vitro and in vivo. Br J Haematol 1970; 19: 559–71.
40. FitzGerald GA, Friedman LA, Miyamori I, O'Grady J, Lewis PJ. A double blind placebo controlled crossover study of prostacyclin in man. Life Sci 1979; 25: 665–72.
41. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057–8.
42. Stamler JS, Mendelsohn ME, Amarante P, et al. N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989; 65: 789–95.
43. Lam JY, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: a new antithrombotic role for an old drug. Circulation 1988; 78: 712–6.
44. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328–38.
45. Bellinger DA, Nichols TC, Read MS, et al. Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci U S A 1987; 84: 8100–4.
46. Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639–42.
47. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79: 657–65.
48. Kelly AB, Hanson SR, Marzec U, Harker LA. Recombinant hirudin (r-H) interruption of platelet-dependent thrombus formation. Circulation 1988; 78: Suppl II: II-311. abstract.
49. Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci U S A 1988; 85: 3184–8.
50. Coller BS. Report of the working party on hybridoma-derived monoclonal antibodies to platelets. Thromb Haemost 1984; 51: 169–73.
51. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet recognition site on human fibrinogen: synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 1984; 23: 1767–74.
52. Huang T-F, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin: a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb–IIIa complex. J Biol Chem 1987; 262: 16157–63.
53. Gan Z-R, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA. Echistatin: a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem 1988; 263: 19827–32.
54. Rao GH, Johnson GJ, White JG. Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prostaglandins Med 1980; 5: 45–58.
55. Folts JD, Rowe GG. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res 1988; 50: 507–16.
56. Buttrick PM, Forscher CA, Sussman II, Mueller HS. Sub-aggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation. Am Heart J 1985; 109: 1258–63.
57. Karlsker RP, Cryer PE, Roberts R. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. Am Heart J 1981; 102: 24–9.
58. Thorsen S, Brakman P, Astrup T. Influence of platelets on fibrinolysis: a critical review. In: Ambrole JL, ed. Hematologic reviews. Vol. 3. New York: Marcel Dekker, 1972:123–79.
59. Joist JH. Platelets and fibrinolysis. Thromb Haemost 1977; 38: 955–62.
60. Jeanneau C, Sultan Y. Tissue plasminogen activator in human megakaryocytes and platelets: immunocytochemical localization, immunoblotting and zymographic analysis. Thromb Haemost 1988; 59: 529–34.
61. Park S, Harker LA, Marzec UM, Levin EG. Demonstration of single chain urokinase-type plasminogen activator on human platelet membrane. Blood 1989; 73: 1421–5.
62. Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303–11.
63. Miles LA, Ginsberg MH, White JG, Plow EF. Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest 1986; 77: 2001–9.
64. Silverstein RL, Leung LLK, Harpel PC, Nachman RL. Complex formation of platelet thrombospondin with plasminogen: modulation of activation by tissue activator. J Clin Invest 1984; 74: 1625–33.
65. Carroll RC, Radcliffe RD, Taylor FB Jr, Gerrard JM. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis: reconstitution and patient studies. J Lab Clin Med 1982; 100: 986–96.
66. Deguchi K, Murashima S, Shirakawa S, et al. The potentiating effect of platelets on plasminogen activation by tissue plasminogen activator. Thromb Res 1985; 40: 853–61.
67. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986; 68: 275–80.
68. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465–72.
69. Kruithof EK, Tran-Thang C, Bachmann F. Studies on the release of plasminogen activator inhibitor from human platelets. Thromb Haemost 1986; 55: 201–5.
70. Plow EF, Collen D. The presence and release of α2-antiplasmin from human platelets. Blood 1981; 58: 1069–74.
71. Smariga PE, Maynard JR. Purification of a platelet protein which stimulates fibrinolytic inhibition and tissue factor in human fibroblasts. J Biol Chem 1982; 257: 11960–5.
72. Francis CW, Marder VJ. Rapid formation of large molecular weight α-polymers in cross-linked fibrin induced by high factor XIII concentrations: role of platelet factor XIII. J Clin Invest 1987; 80: 1459–65.
73. Sakata Y, Aoki N. Significance of cross-linking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536–42.
74. Jang I-K, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920–8.
75. Cronberg S. Effect of fibrinolysis on adhesion and aggregation of human platelets. Thromb Diath Haemorrh 1968; 19: 474–82.
76. Niewiarowski S, Senyi AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction: effects on hemostasis. J Clin Invest 1973; 52: 1647–59.
77. Schafer AI, Maas AK, Ware JA, Johnson PC, Rittenhouse SE, Salzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest 1986; 78: 73–9.
78. Ohlstein EH, Storer B, Fujita T, Shebuski RJ. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit. Thromb Res 1987; 46: 575–85.
79. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142–50.
80. Shebuski RJ, Bloom JC, Sellers TS, et al. Attenuation of the inhibitory effect of prostacyclin on platelet function after tissue plasminogen activator or streptokinase infusion in the rabbit. Fibrinolysis 1989; 3: 115–23.
81. Kerins PM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet activation and depressed prostacyclin (PGI2) biosynthesis following reperfusion with tissue-type plasminogen activator (t-PA) in man. Circulation 1988; 78: Suppl II: II-508. abstract.
82. Schafer AI, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 1985; 75: 456–61.
83. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 1985; 65: 32–40.
84. Schafer AI, Zavoico GB, Loscalzo J, Maas AK. Synergistic inhibition of platelet activation by plasmin and prostaglandin I2. Blood 1987; 69: 1504–7.
85. Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749–55.
86. Stamler JS, Vaughan DE, Loscalzo J. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin. Circ Res 1989; 65: 796–804.
87. Folts JD, Schwartz BS, Kroll M, Schafer AI. Inhibition of platelet thrombus formation in stenosed dog coronary arteries by streptokinase. Circulation 1988; 78: Suppl II: II-313. abstract.
88. Rudd MA, Amarante P, Smick D, Vaughan DE, Loscalzo J. Temporal effects of tissue plasminogen activator infusion on platelet aggregation ex vivo. Blood 1988; 72: Suppl I: 374A. abstract.
89. Loscalzo J. Platelets and thrombolysis. J Vase Med Biol (in press).
90. Rudd MA, George D, Amarante P, Vaughan DE, Loscalzo J. The temporal effects of tissue plasminogen activator infusion on platelet aggregation ex vivo and their modulation by prostaglandin El. Clin Res 1989; 37: 291A. abstract.
91. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987; 10: 527–9.
92. Owen J, Friedman KD, Grossman BA, Wilkins C. Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616–20.
93. Weitz JI, Cruickshank MK, Thong B, et al. Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 1988; 82: 1700–7.
94. Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion following reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284–91.
95. Adnot S, Ferry N, Hanoune J, Lacombe ML. Plasmin: a possible physiological modulator of human platelet adenylate cyclase system. Clin Sci 1987; 72: 467–73.
96. Greenberg JP, Packham MA, Guccione MA, Rand ML, Reimers HJ, Mustard JF. Survival of rabbit-platelets treated in vitro with chymotrypsin, plasmin, trypsin, or neuraminidase. Blood 1979; 53: 916–27.
97. Michelson AD, Barnard MR, Rybak ME, Gore JM, Cola CA. In vivo infusion of recombinant tissue-type plasminogen activator results in a redistribution of platelet glycoprotein Ib stores. Circulation 1988; 78: Suppl II: II-620. abstract.
98. Federici AB, Berkowitz SD, Mannucci PM, Lotto A, Italian P.A.I.M.S. Group, Zimmerman TS. Proteolysis of von Willebrand factor in patients undergoing thrombolytic therapy. Circulation 1988; 78: Suppl II: II-120. abstract.
99. Winocour PD, Kinlough-Rathbone RL, Richardson M, Mustard JF. Reversal of shortened platelet survival in rats by the antifibrinolytic agent, epsilon aminocaproic acid. J Clin Invest 1983; 71: 159–64.
100. Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999–1005.
101. Kowalski E, Kopeć M, Wegrzynowicz A. Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thromb Diath Haemorrh 1963; 10: 406–23.
102. Gimple LW, Gold HK, Leinbach RC, et al. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 80: 581–8.
103. Vaughan DE, Declerck PJ, De Mol M, Collen D. Recombinant plasminogen activator inhibitor1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. J Clin Invest 1989; 84: 586–91.
104. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1–11.
105. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988; 85: 353–9.
106. Harrison DG, Ferguson DW, Collins SM, et al. Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation 1984; 69: 991–9.
107. Gold HK, Leinbach RC, Garabedian HD, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 1986; 73: 347–52.
108. Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis: evidence that platelet activation and THROMBOXANE A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res 1989; 65: 83–94.
109. Gold HK. Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670–7.
110. Mickelson JK, Simpson PJ, Gallas MT, Lucchesi BR. Thromboxane synthase inhibition with CGS 13080 improves coronary blood flow after streptokinase-induced thrombolysis. Am Heart J 1987; 113: 1345–52.
111. Shebuski RJ, Storer BL, Fujita T. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res 1988; 52: 381–92.
112. Shebuski RJ. Smith JM Jr, Storer BL, Granen JR, Bugelski PJ. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. J Pharmacol Exp Ther 1988; 246: 790–6.
113. Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77: 678–84.
114. Golino P, Yao SK, Rosolowsky M, De Clerck F, Buja LM, Willerson JT. Simultaneous blockade of thromboxane A2 receptors and inhibition of thromboxane A2 synthase is more effective in enhancing thrombolysis and preventing reocclusion after tissue plasminogen activator than blockade of thromboxane A2 receptors alone. Clin Res 1989; 37: 518A. abstract.
115. Fitzgerald DJ, Kerins DM, FitzGerald GA. Coronary reocclusion following therapeutic thrombolysis: prevention by thromboxane antagonism and thrombin inhibition. Clin Res 1989; 37: 257A. abstract.
116. Schumacher WA, Lee EC, Lucchesi BR. Augmentation of streptokinaseinduced thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol 1985; 7: 739–46.
117. Vaughan DE, Plavin SR, Schafer AI, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73: 1213–7.
118. Golino P, Focaccio A, Eidt J, Buja LM, Willerson JT. Iloprost reduces the time to thrombolysis and alters reocclusion after t-PA in a canine model of coronary thrombosis. Circulation 1988; 78: Suppl II: II-16. abstract.
119. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101–8.
120. Coller BS, Scudder LE. Inhibition of dog platelet function by in vivo infusion of F(ab′)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985; 66: 1456–9.
121. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783–6.
122. Coller BS, Scudder LE, Berger HJ, Iuliucci JD. Inhibition of human platelet function in vivo with a monoclonal antibody: with observations on the newly dead as experimental subjects. Ann Intern Med 1988; 109: 635–8.
123. Coller BS, Folts JD, Smith SR, Scudder LE. Abolition of in vivo platelet thrombus formation with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with platelet aggregation and bleeding time. Thromb Haemost 1987; 58: 244. abstract.
124. Gold HK, Gimple L, Yasuda T, et al. Phase I human trial of the potent antiplatelet agent, 7E3-F(ab′)2, a monoclonal antibody to the GPIIb/IIIa receptor. Circulation 1989; 80: Suppl II: II-267.
125. Strony JT, Folts JD, Adelman B. In vivo antiplatelet effect of Gly-Arg-Gly-Asp-Ser in the stenosed canine coronary occlusion model. Clin Res 1989; 37: 308A. abstract.
126. Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989; 21: 393–405.
127. Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GBJ. A monoclonal antibody to the platelet receptor GPIIb/IIIa (7E3) prevents acute thrombosis in a canine model of coronary angioplasty. Circulation 1988; 78: Suppl II: II-289. abstract.
128. Hanson SR, Pareti FI, Ruggeri ZM, et al. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988; 81: 149–58.
129. Torem S, Schneider PA, Hanson SR. Monoclonal antibody-induced inhibition of platelet function: effects on hemostasis and vascular graft thrombosis in baboons. J Vasc Surg 1988; 7: 172–80.
130. Cheseboro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation 1987; 76: 142–54.
131. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
132. Cercek B, Lew AS, Hod H, Yano J, Reddy NK, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583–7.
133. Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. Biochemistry 1986; 25: 4033–40.
134. Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281–6.
135. Topol EJ, O'Neill WW, Langburd AB, et al. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation 1987; 75: 420–8.
136. White HD, Rivers JT, Maslowski AH. et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 1989; 320: 817–21.
137. Van de Werf F. Lessons from the European cooperative recombinant tissue plasminogen activator (rt-PA) versus placebo trial. J Am Coll Cardiol 1988; 12: Suppl A: 14A–19A.
138. Thompson PL, Robinson JS. Stroke after acute myocardial infarction: relation to infarct size. Br Med J 1978; 2: 457–9.
139. Puletti M, Morocutti C, Tronca M, et al. Cerebrovascular accidents in acute myocardial infarction. Ital J Neurol Sci 1987; 8: 245–8.
140. Robertson TL, Forman SA, Williams DO, Dodge HT, TIMI Research Group. Aspirin, rt-PA, and reperfusion in AMI: a TIMI observational study. Circulation 1988; 78: Suppl II: II-128. abstract.
141. Uchida Y, Hanai T, Hasegawa K, Kawamura K, Oshima T. Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Adv Prostaglandin Thromboxane Leukotriene Res 1983; 11: 377–83.
142. Blaskó G, Berentey E, Harsányi A, Sas G. Intracoronarily administered prostacyclin and streptokinase for treatment of myocardial infarction. Adv Prostaglandin Thromboxane Leukotriene Res 1983; 11: 385–90.
143. Sharma B, Wyeth RP, Gimenez HJ. Franciosa JA. Intracoronary prostaglandin E1 plus streptokinase in acute myocardial infarction. Am J Cardiol 1986; 58: 1161–6.
144. Sharma B, Wyeth RP, Heinemann FM, Bissett JK. Addition of intracoronary prostaglandin E1 to streptokinase improves thrombolysis and left ventricular function in acute myocardial infarction. J Am Coll Cardiol 1988; 11: Suppl A: 104A. abstract.
145. Topol EJ, Ellis SG, George BS, et al. Combined prostacyclin and tissue plasminogen activator therapy for acute myocardial infarction: evidence for a new drug-drug interaction. Circulation 1988; 78: Suppl II: II-303. abstract.
146. Kerins DM, FitzGerald GA, Fitzgerald DJ. Interaction of a prostacyclin analog and tissue plasminogen activator (t-PA) during coronary thrombolysis. Clin Res 1989; 37: 271A. abstract.
147. Crutchley DJ, Conanan LB, Maynard JR. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1, E2, and I2. J Pharmacol Exp Ther 1982; 222: 544–9.